These results are of clinical importance as dabrafenib could directly impact its own metabolism or the metabolism of other drugs or medications, in particular MEK inhibitors such as trametinib that is approved in combination with dabrafenib for the treatment of metastatic melanoma. The gene discussed is MAP2K7; the disease is metastatic melanoma.